Tribune News Service
New Delhi, January 3
Bharat Biotech on Sunday said the approval of Covaxin for emergency use was a giant leap for India in innovation. Dr Balram Bhargava, chief of the ICMR, said it was a red-letter day for the Indian science and a great moment for low and middle-income nations, as India readies to supply the first indigenous Covid vaccine at home and abroad.
Bharat Biotech has an understanding with 10 countries for Covaxin supplies.
Commenting on concerns over the efficacy data for Covaxin, which is yet to undergo Phase-III trials, Bhargava said, “Safety has been shown in Phase-I and II trials and 22,000 of the 26,000 Phase-III participants have been vaccinated.”
Bharat Biotech’s Krishna Ella said, “Covaxin addresses an unmet medical need during this pandemic and our goal is to provide global access to populations that need it the most. Covaxin has generated excellent safety data with robust immune responses to multiple viral proteins that persist.”